MCM
HZNP

Mazama Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Mazama Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-810
Closed -$21K – 321
2015
Q1 		$21K Buy
+810
New +$14.8K ﹤0.01% 254

Other funds holding HZNP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Mazama Capital Management's HZNP Position: Q2 2015 in Review

Mazama Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2015, closing a stake of 810 shares — an estimated $21K sold.

Mazama Capital Management first reported a position in HZNP in Q1 2015 and held it in 1 quarter. The position peaked at $21K in Q1 2015. 213 funds tracked by Wall St. Rank hold HZNP as of Q2 2015.

  • Mazama Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2015 after selling out during the quarter.
  • Mazama Capital Management sold 810 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2015, an estimated $21K.
  • Mazama Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2015 and held it in 1 quarter.
  • Mazama Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $21K in Q1 2015.
  • 213 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2015.

Based on Mazama Capital Management's 13F filing for Q2 2015, filed 24 Aug 2015.